Although Gacos is satisfied with clinical data, investors ar...

Although Gacos is satisfied with clinical data, investors are worried about the cautious pace of commercialization. Financial reports show that there was no significant increase in revenue, losses of about 166 million, and a decrease in cash flow of about 675 million dollars. The core product Grarese market is fiercely competitive, and it may not have a first-mover advantage in the market after listing.